HTA of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme

Record ID 32018002355
English
Authors' objectives: The National Screening Advisory Committee (NSAC) was established in 2019 by the Minister for Health as an independent advisory committee to play a significant strategic role in the development and consideration of population-based screening programmes in Ireland. At the request of the Department of Health, the Health Technology Assessment (HTA) directorate within the Health Information and Quality Authority (HIQA) undertakes evidence synthesis and provides evidence-based advice to NSAC on behalf of the Minister for Health. In September 2021, NSAC requested that HIQA undertake a health technology assessment of the potential addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme (NNBSP) in Ireland. The protocol document outlines the evidence synthesis approach that HIQA’s evaluation team will use to complete this piece of work.
Details
Project Status: Ongoing
Anticipated Publish Date: 2022
Requestor: National Screening Advisory Committee (NSAC)
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Ireland
MeSH Terms
  • Neonatal Screening
  • Infant, Newborn
  • Hematopoietic Stem Cell Transplantation
  • Severe Combined Immunodeficiency
Contact
Organisation Name: Health Information and Quality Authority (HIQA)
Contact Address: Health Information and Quality Authority, George's Court, George's Lane,Smithfield, Dublin 7. PH : + 353 (01) 814 7464
Contact Name: info@hiqa.ie
Contact Email: info@hiqa.ie
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.